Susquehanna Fundamental Investments LLC Purchases Shares of 215,871 Sage Therapeutics, Inc. (NASDAQ:SAGE)

Susquehanna Fundamental Investments LLC bought a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 215,871 shares of the biopharmaceutical company's stock, valued at approximately $1,172,000. Susquehanna Fundamental Investments LLC owned approximately 0.35% of Sage Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Federated Hermes Inc. lifted its position in Sage Therapeutics by 63.7% in the 4th quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company's stock worth $6,004,000 after buying an additional 430,432 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Sage Therapeutics in the fourth quarter worth $759,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Sage Therapeutics by 157.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company's stock worth $918,000 after acquiring an additional 103,495 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Sage Therapeutics by 108.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after acquiring an additional 38,876 shares in the last quarter. Finally, Martingale Asset Management L P boosted its position in Sage Therapeutics by 70.3% during the fourth quarter. Martingale Asset Management L P now owns 80,183 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 33,106 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company's stock.

Sage Therapeutics Stock Performance

Shares of SAGE traded down $0.08 during mid-day trading on Wednesday, hitting $6.79. The company's stock had a trading volume of 97,660 shares, compared to its average volume of 1,218,859. The stock's 50-day moving average is $7.54 and its two-hundred day moving average is $6.77. The firm has a market capitalization of $424.88 million, a PE ratio of -1.03 and a beta of 0.20. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $13.47.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The company had revenue of $14.06 million during the quarter, compared to the consensus estimate of $14.12 million. During the same period last year, the company earned ($1.80) earnings per share. Sage Therapeutics's revenue for the quarter was up 78.0% on a year-over-year basis. Analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SAGE. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Scotiabank dropped their price objective on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Wedbush reiterated a "neutral" rating and issued a $6.00 target price on shares of Sage Therapeutics in a research note on Wednesday, February 12th. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 2nd. Finally, HC Wainwright restated a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Two analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Sage Therapeutics has a consensus rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.